The US Food and Drug Administration has cleared BlackfinBio's investigational new drug (IND) application for a Phase I/II trial of BFB-101, an adeno-associated virus gene therapy designed to treat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback